Featured Research

from universities, journals, and other organizations

Study questions hypothermia treatment for cardiac arrest

Date:
November 18, 2013
Source:
Lund University
Summary:
Therapeutic hypothermia – cooling the body and brain down to 33C – is the method used worldwide to treat cardiac arrest, even though a lower body temperature may raise the risk of side-effects. However, keeping the temperature steady at 36C is just as effective.

Therapeutic hypothermia -- cooling the body and brain down to 33C -- is the method used worldwide to treat cardiac arrest, even though a lower body temperature may raise the risk of side-effects. However, keeping the temperature steady at 36C is just as effective, a study led by Lund University researchers has found.

"Our results show that it is just as effective -- both for survival and recovery of neurological function -- to focus on avoiding the fever that accompanies cardiac arrest. We don't need to cool down the body and brain to 33C. This is of course important because cooling to lower temperatures brings a higher risk of infection, bleeding and other side-effects," said Niklas Nielsen, researcher at Lund University and first author of the study.

Patients who come into hospital in cardiac arrest receive intensive care with cooling and ventilator treatment. Around half of them survive. Daily life goes quite well for those who survive, but around 30 per cent of cardiac arrest patients suffer impaired cognitive function, for example poorer memory.

"Until now, there has not been a clear place in the health service for the rehabilitation of these patients and one of our most important tasks is to identify them and tailor rehabilitation treatment to them. The median age for cardiac arrest is just over 60, and there are quite a lot of younger people who are affected. Rehabilitation can mean the difference between being able to go back to work and remaining on sick leave," said Niklas Nielsen.

The researchers are planning to analyze the patient data in more detail to see if there may be groups of patients for whom cooling could be beneficial and whether it has an impact at a more detailed cognitive level.


Story Source:

The above story is based on materials provided by Lund University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Niklas Nielsen et al. Targeted Temperature Management Cardiac Arrest. New England Journal of Medicine, November 2013

Cite This Page:

Lund University. "Study questions hypothermia treatment for cardiac arrest." ScienceDaily. ScienceDaily, 18 November 2013. <www.sciencedaily.com/releases/2013/11/131118162551.htm>.
Lund University. (2013, November 18). Study questions hypothermia treatment for cardiac arrest. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2013/11/131118162551.htm
Lund University. "Study questions hypothermia treatment for cardiac arrest." ScienceDaily. www.sciencedaily.com/releases/2013/11/131118162551.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins